Corrective and preventive action is the engine of a pharmaceutical quality system. ICH Q10 describes it as one of the four elements that drive continual improvement, alongside process performance monitoring, change management and management review. EU GMP Chapter 1 expects the effectiveness of CAPAs to be monitored and assessed, and in the US, 21 CFR 211.192 requires investigations into unexplained discrepancies to be thorough and to extend to other batches that may be affected.
None of these texts prescribes a template, which is why inspection findings in this area are so consistent. The same patterns appear again and again: CAPAs closed on the due date with no evidence beyond “training completed”; repeat deviations with the same root cause raised months after the CAPA that should have prevented them; and effectiveness checks that simply restate the action (“SOP revised — effective”) rather than test whether the outcome changed.
An inspector reading your CAPA log is effectively asking one question: when you found a problem, did you make it go away? A well-designed effectiveness check is the only part of the record that answers it.